Blanco:
http://finance.yahoo.com/q/bc?s=PFE&t=6m
kahljorn there were actually two charges brought against the subsidiary- one was that a 12 million dollar kickback was given to a pharmacy benefit manager to add Genotropin to a list of reccomended products to health insurers, the second charge was that Genotropin was being promoted for uses not approved by the FDA.
Threaded Mode
